Amgen 2Q Revenues: $3.6 billion (+14%) 2Q Earnings: $14 million (earnings were $1 billion in 2Q2005)* YTD Revenues: $6.8 billion (+13%) YTD Earnings: $1 billion (-46%) Comments: Worldwide sales of Aranesp increased 26% to $1 billion and combined sales of Neulasta and Neupogen increased 12% to $1 billion in the quarter. North America sales of Enbrel increased 13% to $724 million. Sales of Epogen were down 5% to $613 million. R&D expenses increased 29% to $729 million in t...